Program: Booth presentations

Location

UPDATE FOR THE PRESENTERS
Log into the submitter’s account on platform.isad.org, click “My Beijing 2026,” and select your abstract title to proceed with the next steps (upload of the files).

The preview room accepts files, but a 4-hour lead time is required; please plan accordingly if you need an update.

Floor map & Schedule

Please note all timings are based on Beijing time zone.
➜ China Standard Time (CST) – UTC+8

Poster/#ref	Date & Time	Presenter/Title RESET
October 17	09:30	Booth Presentations in Break Session 1
Poster booth A
P1-A1 P—#2259	2026-10-17 09:30 · 7 min.	Shijia RAO Increased peripheral monocytes mark a distinct inflammatory subtype of adult atopic dermatitis
P1-A2 P—#2228	2026-10-17 09:37 · 7 min.	Mengyao YANG AG-30/5C Enhances Tight Junction Barrier Function and Ameliorates Atopic Dermatitis-like Skin Inflammation
P1-A3 P—#2149	2026-10-17 09:44 · 7 min.	Weronika ZYSK Real-world effectiveness of lebrikizumab for head and neck involvement in moderate-to-severe atopic dermatitis
P1-A4 P—#2316	2026-10-17 09:51 · 7 min.	Xin TIAN Real-World Utilization of Upadacitinib in Atopic Dermatitis and Achievement of Minimal Disease Activity in China: 1-Year Interim Analysis of REACH-AD Study
P1-A5 P—#2023	2026-10-17 09:58 · 7 min.	Ronald Orutwa ONDARI Stigma and Cultural Misconceptions Surrounding Atopic Dermatitis in Southwestern Kenya: A Multispecialty Approach to Community Health, Psychological Well-Being, Nutritional Care, and Social Inclusion
Poster booth B
P1-B1 P—#2039	2026-10-17 09:30 · 7 min.	Yik Weng YEW Continuous nemolizumab treatment achieved sustained, clinically meaningful improvements through week 48 across multiple domains, including skin clearance, itch, sleep, and quality of life
P1-B2 P—#2174	2026-10-17 09:37 · 7 min.	Yumei LIU Longitudinal Plasma Proteomics Reveals Restoration of Immune and Barrier Function in Atopic Dermatitis Patients Treated with Upadacitinib
P1-B3 P—#2170	2026-10-17 09:44 · 7 min.	Shuting DENG Butyrate alleviates itch and inflammation in atopic dermatitis by inhibiting TRPV1 channels and NPPB release
P1-B4 P—#2031	2026-10-17 09:51 · 7 min.	Theresa DONHAUSER Quality of outcome measurement instruments assessing quality of life in children and adults with atopic eczema: A systematic review update 3.0
P1-B5 P—#2198	2026-10-17 09:58 · 7 min.	Mengmeng LI Stapokibart Improves Atopic Dermatitis Worsening During Mepolizumab Therapy in Eosinophilic Granulomatosis With Polyangiitis
Poster booth C
P1-C1 P—#2315	2026-10-17 09:30 · 7 min.	Yi XIAO The OX40 Axis Links Chronic Inflammation to Adult-Onset Atopic Dermatitis: A Real-World Multi-Omics Study
P1-C2 P—#2248	2026-10-17 09:37 · 7 min.	Ying ZOU HEK293T Cell-Derived Extracellular Vesicles with High PD-L1 and E-cadherin Expression for Atopic Dermatitis Treatment by Regulating CD4+Tissue-Resident Memory T Cells
P1-C3 P—#2083	2026-10-17 09:44 · 7 min.	So Hee PARK Mesenchymal Stem Cells Differentially Reprograms Keratinocyte Responses in Therapeutic and Preventive Models of Atopic Dermatitis
P1-C4 P—#2340	2026-10-17 09:51 · 7 min.	Junquan WANG A case of DRESS with CMV pneumonia misdiagnosed as atopic dermatitis
P1-C5 P—#2090	2026-10-17 09:58 · 7 min.	Gloria Elisante MASENGA Burden, Trends and Seasonal Patterns of Atopic Dermatitis at Tanzania’s National Dermatology Referral Centre: A Six-Year Retrospective Study.
Poster booth D
P1-D1 P—#2327	2026-10-17 09:30 · 7 min.	Juan XIANG Unmasking Hidden Sensitizers: Two Pediatric Cases of Systemic Contact Dermatitis Masquerading as Atopic Dermatitis
P1-D2 P—#2099	2026-10-17 09:37 · 7 min.	Yujin LEE Keratinocyte Heparan Sulfate Maintains Epidermal Barrier Homeostasis and Restrains CXCL10-Dependent T-cell Recruitment
P1-D3 P—#2137	2026-10-17 09:44 · 7 min.	Yingxue HE Necroptotic Signalling in Epidermal Differentiation and Repair: Implications for Atopic Dermatitis Pathogenesis and Therapeutic Targeting
P1-D4 P—#2041	2026-10-17 09:51 · 7 min.	Irene SCHOLL Real-World Patient-Reported Pain in Atopic Dermatitis: insights from the TREAT NL/BE registry
P1-D5 P—#2167	2026-10-17 09:58 · 7 min.	Andrianandrianina Mbolatiana Kiady Armando RAKOTOMANANA Therapeutic journey prior to methotrexate initiation in atopic dermatitis: A cross-sectional study in Madagascar
Poster booth E
P1-E1 P—#2244	2026-10-17 09:30 · 7 min.	Zhiru ZHOU The Spectrum of Infectious Contributions to Atopic Dermatitis: A Prospective Cohort and Experimental Study
P1-E2 P—#2094	2026-10-17 09:37 · 7 min.	Kaï Bérénice Esthelle DÉGBOÉ Disease control and its baseline predictors at follow-up in adult atopic dermatitis in Benin: high attrition and the weight of depression
P1-E3 P—#2121	2026-10-17 09:44 · 7 min.	Xin Yi NG Nocturnal scratching, sleep and brain network connectivity in atopic dermatitis
P1-E4 P—#2281	2026-10-17 09:51 · 7 min.	Wenjing JIANG DNA methylation analyses provide insights into immune regulation, epithelial barrier dysfunction, and neuroimmune signaling in hand eczema
P1-E5 P—#2143	2026-10-17 09:58 · 7 min.	Isabel TAPIA FLG2 in Atopic dermatitis: Findings from Swedish, Ethiopian and Colombian cohorts
Poster booth F
P1-F1 P—#2066	2026-10-17 09:30 · 7 min.	So-yeon YUN The Potential Mechanistic Link and Therapeutic Implications Between Obesity and Atopic Dermatitis in Mouse Models
P1-F2 P—#2257	2026-10-17 09:37 · 7 min.	Ansheng XIE Longitudinal spatial transcriptomic profiling before and after dupilumab in a patient diagnosed with cutaneous T-cell lymphoma
P1-F3 P—#2303	2026-10-17 09:44 · 7 min.	Yang Yang LUO Eczema Herpeticum: A Retrospective Analysis of 91 Cases —— Clinical Characteristics, Predisposing Factors and Treatment Outcomes
P1-F4 P—#2061	2026-10-17 09:51 · 7 min.	Suzanne KEDDIE Estimating the prevalence of atopic dermatitis 1992-2026: a systematic review and meta-analysis
P1-F5 P—#2165	2026-10-17 09:58 · 7 min.	Eric SIMPSON Adult Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab Achieve Sustained Optimal Control of Signs and Symptoms: Results From a 5-Year Open-Label Extension Study
October 17	15:35	Booth Presentations in Break Session 2
Poster booth A
P2-A1 P—#2280	2026-10-17 15:35 · 7 min.	Chen WANG BAX Disrupted Mitochondrial-Derived Vesicle–Mediated Mitophagy in Atopic Dermatitis
P2-A2 P—#2160	2026-10-17 15:42 · 7 min.	Nafisah Oyinkansola AKIM-SHITTU Dermcidin as a potential regulator of epidermal barrier homeostasis and a possible therapeutic target in atopic dermatitis
P2-A3 P—#2030	2026-10-17 15:49 · 7 min.	Xinming MAI Systemic Inflammatory Indicators and Their Clinical Correlations in Prurigo Nodularis: A Multi-Center Cross-Sectional Study in China
P2-A4 P—#2085	2026-10-17 15:56 · 7 min.	Yimeng WANG A phase 1 study of a novel oral interleukin-1 receptor–associated kinase 4 (IRAK4) degrader QLS12010 in patients with moderate-to-severe atopic dermatitis (AD)
Poster booth B
P2-B1 P—#2270	2026-10-17 15:35 · 7 min.	Ya-Xuan ZHU TGM3 regulates IL-33 expression via the PI3K-Akt signaling pathway to mediate inflammatory responses in keratinocytes
P2-B2 P—#2087	2026-10-17 15:42 · 7 min.	Volatantely Tobiniaina RATOVONJANAHARY Sex-Based Discordance Between Objective Severity and Patient-Reported Burden in Atopic Dermatitis
P2-B3 P—#2291	2026-10-17 15:49 · 7 min.	Chang JUI-WEN Resting-State Neural Oscillatory Signatures of Atopic Dermatitis: Associations with Itch, Disease Severity, Negative Emotion, and Impulsivity
P2-B4 P—#2339	2026-10-17 15:56 · 7 min.	Yinli ZHOU Associations of Serum Androgen with Late-Onset Male Atopic Dermatitis: Prospective Cohorts Study and Clinical Validation
P2-B5 P—#2064	2026-10-17 16:03 · 7 min.	Chin-Yi YANG Effectiveness and Achievement of Minimal Disease Activity with Upadacitinib in Adults and Adolescents with Atopic Dermatitis: 18-Month Interim Analysis of the Real-World Multicountry AD-VISE Study
Poster booth C
P2-C1 P—#2249	2026-10-17 15:35 · 7 min.	Jade GAMELIN-KAO Filaggrin (FLG) Gene Mutations in Asian Populations with Atopic Dermatitis: A Systematic Review and Meta-Analysis
P2-C2 P—#2299	2026-10-17 15:42 · 7 min.	Li WAN Non-invasive prediction of dupilumab response in facial atopic dermatitis using early post-treatment reflectance confocal microscopy features
P2-C3 P—#2049	2026-10-17 15:49 · 7 min.	Yun-Ji LEE Long-term efficacy, safety, and predictive factors for response to upadacitinib in moderate-to-severe atopic dermatitis: A real-world retrospective study
P2-C4 P—#2294	2026-10-17 15:56 · 7 min.	Xinying CAI Application of Co/Mn Metal-Organic Framework Nanozyme in the Treatment of Atopic Dermatitis
P2-C5 P—#2118	2026-10-17 16:03 · 7 min.	Neal KOLLER Zabalafin, a Novel Topical Multitarget Therapeutic Drug for the Treatment of Atopic Dermatitis
Poster booth D
P2-D1 P—#2199	2026-10-17 15:35 · 7 min.	Samantha KUROSKY Short-term efficacy of abrocitinib vs ivarmacitinib in moderate-to-severe atopic dermatitis: an anchored matching-adjusted indirect comparison
P2-D2 P—#2179	2026-10-17 15:42 · 7 min.	Ye HE Clinical Characteristics and Biomarkers of Super-Response to Dupilumab in Patients with Refractory Atopic Dermatitis: A Single-Center Retrospective Study
P2-D3 P—#2008	2026-10-17 15:49 · 7 min.	Sung Beom CHUNG Response of Biologics and JAK inhibitors in Severe Atopic Dermatitis in Real World: Patient and Body Region-Specific Eczema Area and Severity Index Outcomes from a Korean Multicenter Cohort
P2-D4 P—#2072	2026-10-17 15:56 · 7 min.	Ousmane FAYE Diagnostic Accuracy, Spatial Distribution and Misclassification of Atopic Dermatitis in a National Teledermatology Programme in Mali
P2-D5 P—#2216	2026-10-17 16:03 · 7 min.	Jianyun LU Multi-Omics Integrated Analysis Reveals the Efficacy and Outcome Mechanisms of Acidified Aliphatic Ester in Atopic Dermatitis
Poster booth E
P2-E1 P—#2240	2026-10-17 15:35 · 7 min.	Shengyuan HUA A Real-World Data Study on the Clinical Efficacy and Safety of Dupilumab in the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adolescents aged 5-16 years
P2-E2 P—#2254	2026-10-17 15:42 · 7 min.	Yuan LIANG Safety and Efficacy to Benvitimod Cream 1% in Children Aged 3-24 Months with Atopic Dermatitis
P2-E3 P—#2180	2026-10-17 15:49 · 7 min.	Sami SALAHIA Comparative Efficacy of Systemic and Topical Therapies for Atopic Dermatitis: A Bayesian Network Meta‑Analysis
P2-E4 P—#2237	2026-10-17 15:56 · 7 min.	Chunping SHEN Effects of a repair cream containing artemisia annua extract and rice distiller’s grain extract on skin lesions and skin barrier function in infants aged 29 days to 3 years with mild-to-moderate atopic dermatitis
P2-E5 P—#2116	2026-10-17 16:03 · 7 min.	Yik Weng YEW The Efficacy and Safety Analysis of Topical Ruxolitinib 1.5% Cream on Different Body Sites in Singapore Atopic Dermatitis Patients
Poster booth F
P2-F1 P—#2013	2026-10-17 15:35 · 7 min.	Suping NIU Safety, Tolerability, and Pharmacokinetics of Lebrikizumab in Chinese Healthy Participants
P2-F2 P—#2026	2026-10-17 15:42 · 7 min.	Thiago LENOIR Therapeutic strategies in overlap atopic dermatitis and psoriasis: a narrative review of biologic and JAK inhibitor outcomes
P2-F3 P—#2025	2026-10-17 15:49 · 7 min.	Jennifer AUSTIN Evaluating Patient-Reported Impact of Dermatological Diseases (PRIDD) Measure Among Patients with Atopic Dermatitis/Eczema in a Global Study
P2-F4 P—#2176	2026-10-17 15:56 · 7 min.	Qian ZHOU Clinical Characteristics and Risk Factors of Recurrence During Dupilumab Maintenance Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: A Single-center Real-world Study
P2-F5 P—#2162	2026-10-17 16:03 · 7 min.	Lina IVERT Cutaneous immune-related adverse events in patients with pre-existing atopic dermatitis receiving cancer immunotherapy: a real-world cohort study
October 18	09:10	Booth Presentations in Break Session 3
Poster booth A
P3-A1 P—#2138	2026-10-18 09:10 · 7 min.	Mutong ZHAO Cord Blood Immune Biomarkers Enable Birth-Time Prediction of Atopic Dermatitis: Development and External Validation of a Machine-Learning Model
P3-A2 P—#2055	2026-10-18 09:17 · 7 min.	Saehee KIM Association Between Mode of Delivery and Atopic Dermatitis Risk in Offspring:An Updated Systematic Review and Meta-Analysis
P3-A3 P—#2247	2026-10-18 09:24 · 7 min.	Perpetua Uchechi IBEKWE The Burden of Allergic Comorbidities in Atopic Dermatitis: Findings from a Nigerian Tertiary Dermatology Centre
P3-A4 P—#2125	2026-10-18 09:31 · 7 min.	Chaoying GU Long-term efficacy of abrocitinib through approximately two years in Chinese patients with moderate-to-severe atopic dermatitis: a pooled long-term extension analysis
P3-A5 P—#2344	2026-10-18 09:38 · 7 min.	Isabel Cristina Lima ENCARNAÇÃO Atopic dermatitis in Amazonas- Brazil: prevalence and regional challenges
Poster booth B
P3-B1 P—#2201	2026-10-18 09:10 · 7 min.	Abdul Mannan MUSTAFA Personalized Risk-Stratified Follow-up Improves Childhood Atopic Dermatitis Outcomes in Underserved Communities: A Community-Based Implementation Study
P3-B2 P—#2010	2026-10-18 09:17 · 7 min.	Chaocheng LIU Dual targeted therapy using Janus kinase inhibitors and biologics for atopic dermatitis: A systematic review
P3-B3 P—#2318	2026-10-18 09:24 · 7 min.	Fuchen HUANG Short-term effectiveness of JAK inhibitors versus dupilumab in erythrodermic atopic dermatitis: a real-world retrospective cohort study
P3-B4 P—#2022	2026-10-18 09:31 · 7 min.	Shawn Mandere ORUTWA Social Media Driven Misuse of Topical Treatments and the Rising Burden of Pediatric and Adolescent Atopic Dermatitis in Underserved Communities: Implications for Awareness, Stigma Reduction, and Digital Health Campaigns
P3-B5 P—#2347	2026-10-18 09:38 · 7 min.	Olufolakemi COLE Listening to African Patients’ Voices on Atopic Dermatitis Through Dermatologist-Led Social Media: Understanding Information Needs, Misconceptions and Lived Experiences
Poster booth C
P3-C1 P—#2252	2026-10-18 09:10 · 7 min.	Bocheng WANG Dupilumab modulates TIGIT expression to suppress type 2 inflammatory response in atopic dermatitis
P3-C2 P—#2074	2026-10-18 09:17 · 7 min.	Badjoh Roseline Rocsane TIENDREBEOGO Therapeutic education and atopic dermatitis : results of an experimental program in Burkina Faso
P3-C3 P—#2178	2026-10-18 09:24 · 7 min.	Qian ZHOU Clinical Characteristics of Self-reported Symptom Recurrence After Non-continuation of Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Descriptive Case Series
P3-C4 P—#2037	2026-10-18 09:31 · 7 min.	Fahafahantsoa RAPELANORO RABENJA Efficacy and Safety of Methotrexate in Moderate-to-Severe Atopic Dermatitis in Malagasy Adults
P3-C5 P—#2217	2026-10-18 09:38 · 7 min.	Wanjin KIM RNA Sequencing Reveals Site-Specific Lipid Metabolic Vulnerability Underlying Dupilumab-Associated Head and Neck Dermatitis
Poster booth D
P3-D1 P—#2011	2026-10-18 09:10 · 7 min.	Anna RIMINCHAN Collaborative Care in Dermatology and Allergy/Immunology: A Scoping Review of Immunodermatology Clinic Models, Patient Outcomes, and Implementation Gaps
P3-D2 P—#2197	2026-10-18 09:17 · 7 min.	Huiting ZHU Efficacy of Acupuncture Combined with Bloodletting Therapy for Facial Atopic Dermatitis: A Case Series
P3-D3 P—#2371	2026-10-18 09:24 · 7 min.	Londiwe Nokujabula BUTHELEZI The level of natural moisturising factors in the stratum corneum of African atopic dermatitis patients in KwaZula-Natal, South Africa.
P3-D4 P—#2084	2026-10-18 09:31 · 7 min.	Axel SVEDBOM Disease Severity and Healthcare Costs in Moderate-to-Severe Atopic Dermatitis: A Swedish Register-Based Study
P3-D5 P—#2358	2026-10-18 09:38 · 7 min.	Yuyan ZHANG TMEM232 Promotes Atopic Dermatitis Through CD36 Palmitoylation-Mediated Fatty Acid Metabolic Reprogramming
Poster booth E
P3-E1 P—#2012	2026-10-18 09:10 · 7 min.	Ida VITTRUP Real-world safety and effectiveness of up to 12 months of tralokinumab treatment in 124 patients with atopic dermatitis (AD) aged ≥65 years
P3-E2 P—#2210	2026-10-18 09:17 · 7 min.	Muzna Khalfan MASOUD Delayed diagnosis of atopic dermatitis and its complications in patients with skin of color: A case series from Tanzania
P3-E3 P—#2183	2026-10-18 09:24 · 7 min.	Haihong QIN Efficacy of stapokibart in patients with dupilumab- and/or JAK Inhibitor-refractory facial and neck atopic dermatitis: a prospective case series of 12 patients
P3-E4 P—#2019	2026-10-18 09:31 · 7 min.	Fandresena SENDRASOA Impact of atopic dermatitis on quality of life in adults seen in the department of dermatology at the University Hospital Antananarivo Madagascar.
P3-E5 P—#2356	2026-10-18 09:38 · 7 min.	Ziying HE IL-7/IL-7R Axis Exacerbates Atopic Dermatitis by Promoting Extracellular Trapping Network Formation in Macrophages
Poster booth F
P3-F1 P—#2110	2026-10-18 09:10 · 7 min.	Sébastien BARBAROT A prospective, multicentre, French observational study of the incidence of ophthalmic adverse events in patients treated with tralokinumab for atopic dermatitis. Interim Analysis
P3-F2 P—#2214	2026-10-18 09:17 · 7 min.	Xiaofei GAO Analysis of Disease Improvement in Pediatric Patients with Atopic Dermatitis After Discontinuation of Dupilumab
P3-F3 P—#2062	2026-10-18 09:24 · 7 min.	Mendrika Fifaliana RAKOTOARISAONA Severe Adult-Onset Atopic Dermatitis Revealing HIV Infection in a 33-Year-Old Malagasy Man
P3-F4 P—#2069	2026-10-18 09:31 · 7 min.	Chin-Yi YANG Real-World Safety of Upadacitinib in Adults and Adolescents with Atopic Dermatitis: 12-Month Analysis of the Multicountry Observational AD-VISE Study
P3-F5 P—#2314	2026-10-18 09:38 · 7 min.	Yifei WANG Arachidonic Acid Exacerbates Head and Neck Atopic Dermatitis via CD36-Mediated Lipid Peroxidation in Keratinocytes
October 18	15:15	Booth Presentations in Break Session 4
Poster booth A
P4-A1 P—#2288	2026-10-18 15:15 · 7 min.	Haoran HU Atopic Dermatitis and Hypertension Risk: A Systematic Review and Meta-Analysis of Global Epidemiological Evidence
P4-A2 P—#2093	2026-10-18 15:22 · 7 min.	Kaï Bérénice Esthelle DÉGBOÉ Factors independently associated with severity in adult atopic dermatitis on pigmented skin and the limitations of erythema-based severity scores
P4-A3 P—#2076	2026-10-18 15:29 · 7 min.	Eric SIMPSON Phase 2 study of novel trispecific tilrekimig (PF-07275315) in patients with moderate-severe atopic dermititis: Interim efficacy and safety results at 16 weeks
P4-A4 P—#2185	2026-10-18 15:36 · 7 min.	Shengyuan QU Acupuncture for Chronic Spontaneous Urticaria: A Randomized Controlled Trial
P4-A5 P—#2278	2026-10-18 15:43 · 7 min.	Zelin OU Vulvar Microenvironment-Inspired Pullulan Hydrogel Delivery of Lactobacillus crispatus for Atopic Dermatitis
Poster booth B
P4-B1 P—#2233	2026-10-18 15:15 · 7 min.	Mengyao YI Cold Exposure Exacerbates Atopic Dermatitis through a TRPA1-SREBP1-Unsaturated Fatty Acid Metabolic Reprogramming Axis
P4-B2 P—#2135	2026-10-18 15:22 · 7 min.	Alina TYO Candida albicans-induced itch is linked to a type 2 mast cell - neuro-immune signaling
P4-B3 P—#2220	2026-10-18 15:29 · 7 min.	Yangyiyi YU When Dupilumab Facial Redness hides Demodex: vigilance on long-term IL-4R antagonist therapy
P4-B4 P—#2380	2026-10-18 15:36 · 7 min.	Jan GUTERMUTH Distinct immune and epigenetic signatures predict therapeutic response to Type-2 inflammation inhibition in atopic dermatitis
P4-B5 P—#2261	2026-10-18 15:43 · 7 min.	Bo PENG Distinct CD4⁺ and CD8⁺ Cutaneous TRM Cell Responses in DNCB- and MC903-Induced AD-Like Skin Inflammation
Poster booth C
P4-C1 P—#2129	2026-10-18 15:15 · 7 min.	Yan ZHAO Efficacy of Stapokibart After Dosing Interval Extension in Elderly and Non-Elderly Fast Responders With Moderate-to-Severe Atopic Dermatitis
P4-C2 P—#2336	2026-10-18 15:22 · 7 min.	Mu YUZHU Differences in Baseline Characteristics and Outcomes of Biologic Therapy Among Moderate-to-Severe Atopic Dermatitis Patients Based on Single, Dual, or Multiple Diagnostic Criteria
P4-C3 P—#2032	2026-10-18 15:29 · 7 min.	Zoe Imogen HEMSLEY Comparative Efficacy of Systemic Treatments on Anxiety and Depression Outcomes in Atopic Dermatitis Clinical Trials: A Network Meta-Analysis
P4-C4 P—#2365	2026-10-18 15:36 · 7 min.	Xin TIAN Real-World Utilization of Upadacitinib in Atopic Dermatitis and Achievement of Minimal Disease Activity in China: 1-Year Interim Analysis of REACH-AD Study
P4-C5 P—#2141	2026-10-18 15:43 · 7 min.	Christian APFELBACHER Skin care interventions in infants for preventing eczema and food allergy
Poster booth D
P4-D1 P—#2002	2026-10-18 15:15 · 7 min.	Fenohasina RAKOTONANDRASANA Nutritional status and severity of atopic dermatitis in Malagasy patients
P4-D2 P—#2378	2026-10-18 15:22 · 7 min.	Sixian BAI Shared Inflammatory-Metabolic Microenvironment Links Atopic Dermatitis and Type 2 Diabetes Mellitus: An Integrative Population and Molecular Study
P4-D3 P—#2285	2026-10-18 15:29 · 7 min.	Karl Philipp DREWITZ Revisiting Quality of Life in the HOME Core Outcome Set for Eczema – findings from the HOME XII Consensus Meeting
P4-D5 P—#2001	2026-10-18 15:43 · 7 min.	Jensen YEUNG Treating-to-target in chronic hand eczema: Development of a patient-centric framework
Poster booth E
P4-E1 P—#2212	2026-10-18 15:15 · 7 min.	Xing LU Three-Year Follow-Up of Severe Infantile Atopic Dermatitis with Kaposi‘s Varicelliform Eruption and Growth Delay: A Multidisciplinary Case Report
P4-E2 P—#2151	2026-10-18 15:22 · 7 min.	Tsiory Iarintsoa RAZAFIMAHARO Differences in clinical phenotype of childhood-onset and adult-onset atopic dermatitis in Malagasy adult patients
P4-E3 P—#2104	2026-10-18 15:29 · 7 min.	Yan ZHAO Improvement of Atopic Dermatitis with MG-K10 across different anatomic regions: data from phase III clinical trial
P4-E4 P—#2370	2026-10-18 15:36 · 7 min.	Eric SIMPSON Safety and Efficacy of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody: Proof-of-Concept Results from the Biologic-Naïve Portion of a Double-Blind, Placebo-Controlled Phase I Study in Patients with Atopic Dermatitis
P4-E5 P—#2136	2026-10-18 15:43 · 7 min.	Yijie ZHENG Efficacy and Safety of Moisturizing Cream containing EOP(1), NP(3), & AP(6-II) as Adjuvant Therapy in Pediatric Patients with Mild Atopic Dermatitis: A Multicenter, Randomized, Parallel-Controlled Trial
Poster booth F
P4-F1 P—#2232	2026-10-18 15:15 · 7 min.	Ping CHEN Real-world effectiveness and safety of dupilumab in very young infants with moderate-to-severe atopic dermatitis: a single-center cohort study
P4-F2 P—#2277	2026-10-18 15:22 · 7 min.	Xingbao LUAN Factors associated with systemic therapy in Chinese pediatric atopic dermatitis outpatients: a single-center cross-sectional study
P4-F3 P—#2379	2026-10-18 15:29 · 7 min.	Lena LY Topical Corticosteroid Maintenance for Atopic Dermatitis: An ISAD* Survey (International Society of Atopic Dermatitis)
P4-F4 P—#2192	2026-10-18 15:36 · 7 min.	Qiaochu JIANG Treatment Decision-Making Involvement and Medication Adherence Among Adolescents With Atopic Dermatitis and Their Caregivers: A Paired Cross-Sectional Study
P4-F5 P—#2059	2026-10-18 15:43 · 7 min.	Christian VESTERGAARD Uncovering Patient Priorities in Atopic Dermatitis Through an International Google Trends Analysis
October 19	09:10	Booth Presentations in Break Session 5
Poster booth A
P5-A1 P—#2146	2026-10-19 09:10 · 7 min.	Wenhui WANG Improvements in Symptoms and Severity with Abrocitinib in Adult Patients with Atopic Dermatitis: Long-Term Effectiveness through 64 Weeks from AHEAD Registry
P5-A4 P—#2342	2026-10-19 09:31 · 7 min.	Xiaoyan WANG Allergen Component Sensitization Profiles to House Dust Mite in Patients with Atopic Dermatitis and Their Clinical Significance
P5-A5 P—#2360	2026-10-19 09:38 · 7 min.	Sherzod KHONKHODJAEV Cutaneous Immune Markers and Clinical Severity in Atopic Dermatitis
Poster booth B
P5-B1 P—#2158	2026-10-19 09:10 · 7 min.	Yik Weng YEW Whole-genome sequencing GWASs of skin barrier physiology in a multi-ethnic Asian cohort reveal evidence for common variant genetic architecture
P5-B2 P—#2203	2026-10-19 09:17 · 7 min.	Qingyang ZHAO Risk factors for anxiety/depression in children with atopic dermatitis
P5-B3 P—#2381	2026-10-19 09:24 · 7 min.	Erereoghor OTROFANOWEI Immunologic signatures in an Atopic Dermatitis cohort from Nigeria: Serum MCP-4/CCL13 as a possibly useful surrogate indicator for Severity and Skin-Barrier Dysfunction
P5-B5 P—#2332	2026-10-19 09:38 · 7 min.	Sai YANG Comparison of Clinical Characteristics Between Pediatric/Adolescent and Adult Patients with Alopecia Areata Complicated by Atopic Dermatitis
Poster booth C
P5-C1 P—#2115	2026-10-19 09:10 · 7 min.	Karaked CHANTAWARANGUL Developing a rapid screening tool for atopic dermatitis in the general population: a systematic review and diagnostic test accuracy meta-analysis
P5-C2 P—#2080	2026-10-19 09:17 · 7 min.	Xia DOU Prediction Modeling for Systemic Therapy in Moderate-to-Severe Atopic Dermatitis
P5-C3 P—#2102	2026-10-19 09:24 · 7 min.	Hye-One KIM Lipidomic Profiling of Prurigo Lesional Skin: Ceramide Dysregulation and Triacylglycerol Alterations
P5-C5 P—#2322	2026-10-19 09:38 · 7 min.	Jianping TANG Dust Mite Allergen Component Profiling and Clinical Features of Atopic Dermatitis in Children
Poster booth D
P5-D1 P—#2107	2026-10-19 09:10 · 7 min.	Rong ZENG Neonatal vitamin D levels are associated with specific eczema phenotypes: a prospective population-based study
P5-D2 P—#2003	2026-10-19 09:17 · 7 min.	Vishnupriya KANNAN Atopic dermatitis, depressive and anxiety symptoms, and cognition in 49,972 multi-ethnic Asian adults: cross-sectional findings from the HELIOS cohort
P5-D5 P—#2348	2026-10-19 09:38 · 7 min.	Olufolakemi COLE Skincare Practices and Health-Seeking Behaviour of Patients with Atopic Dermatitis in Lagos, Nigeria
Poster booth E
P5-E1 P—#2372	2026-10-19 09:10 · 7 min.	Mendrika Fifaliana RAKOTOARISAONA Severe Adult-Onset Atopic Dermatitis Revealing HIV Infection in a 33-Year-Old Malagasy Man
P5-E2 P—#2312	2026-10-19 09:17 · 7 min.	Xiaoyun CHEN A Few-Shot Prototype Network ADProNet for Objective Severity Grading of Erythema in Pediatric Atopic Dermatitis
P5-E5 P—#2153	2026-10-19 09:38 · 7 min.	Peimei ZHOU YKL-40 promotes M2 macrophage polarization through PI3K/AKT/STAT3 signaling and exacerbates atopic dermatitis-like inflammation
Poster booth F
P5-F1 P—#2126	2026-10-19 09:10 · 7 min.	Brenda NGO Recognising Atopic Dermatitis in Skin of Colour: An Australian Clinical Perspective
P5-F3 P—#2230	2026-10-19 09:24 · 7 min.	Ao WANG Prevalence of Contact Sensitization in Patients with Atopic Dermatitis: A Retrospective Study from China
P5-F4 P—#2364	2026-10-19 09:31 · 7 min.	Yaojia Zhou Yaojia ZHOU Caregiver Concerns and Nursing Needs in Children with Atopic Dermatitis: A Qualitative Study in Hangzhou, China
P5-F5 P—#2258	2026-10-19 09:38 · 7 min.	Linxi ZENG Role and Molecular Mechanisms of DCIR-Mediated Innate Immune Activation of ILC2s in Atopic Dermatitis
October 19	15:35	Booth Presentations in Break Session 6
Poster booth A
P6-A1 P—#2227	2026-10-19 15:35 · 7 min.	Yan YANG Effect of CFTR-Regulated Th17 Cell Activation on the Skin Barrier in Atopic Dermatitis
P6-A2 P—#2150	2026-10-19 15:42 · 7 min.	Anna Hillert WINTHER The importance of filaggrin gene variants in atopic dermatitis, clinical presentation and severity, from childhood to adulthood
P6-A5 P—#2120	2026-10-19 16:03 · 7 min.	Samson Leophonte RAMILY Triggering factors and severity of atopic dermatitis in Malagasy adults
Poster booth B
P6-B1 P—#2223	2026-10-19 15:35 · 7 min.	Voahanginirina Nathalie RALIMALALA When Atopic dermatitis becomes complicated by crusted scabies : Two Challenging Cases
P6-B2 P—#2213	2026-10-19 15:42 · 7 min.	Dilidaer MAHEMUTI Effectiveness and Safety of Upadacitinib in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center Real-World Retrospective Cohort Study
P6-B5 P—#2164	2026-10-19 16:03 · 7 min.	Yu Ri WOO Onset-Defined Circulating Proteomic Heterogeneity in Early- and Late-Onset Adult Atopic Dermatitis
Poster booth C
P6-C1 P—#2073	2026-10-19 15:35 · 7 min.	Ami SONG Global variation in atopic dermatitis severity distributions: a systematic review and meta-analysis of atopic dermatitis burden in the general population
P6-C2 P—#2235	2026-10-19 15:42 · 7 min.	Ting CAO Activation of LIGHT/HVEM signaling in CD4+ T cells redounds to aggregation of atopic dermatitis
P6-C4 P—#2147	2026-10-19 15:56 · 7 min.	Rachel Adhiambo OGOLA Patient-Reported Outcomes in Atopic Dermatitis Care in Kenya: Integrating Therapeutic Patient Education to Improve Diagnosis and Therapy
P6-C5 P—#2071	2026-10-19 16:03 · 7 min.	Abraham Getachew KELBORE Impact of Atopic Dermatitis on the Quality of Life of Children in Ethiopia: A Multicentre Prospective Cohort Study
Poster booth D
P6-D2 P—#2018	2026-10-19 15:42 · 7 min.	Yannick Mukendi NKESU Atopic dermatitis in sub-Saharan Africa: socio-economic factors and barriers to care in a resource-limited region of the Democratic Republic of Congo DRC.
P6-D4 P—#2048	2026-10-19 15:56 · 7 min.	Alan IRVINE Impact of Dupilumab on Bone Mineralization Biomarker and Growth Metrics in Children Aged 2 to Under 12 Years With Moderate-to-Severe Atopic Dermatitis
P6-D5 P—#2063	2026-10-19 16:03 · 7 min.	Celestin Kouadio AHOGO Atopy school: first experience in french-speaking sub-saharan Africa, acquisitions, challenges and outlook
Poster booth E
P6-E1 P—#2187	2026-10-19 15:35 · 7 min.	Ziyi XIAO Ultra-processed Food Intake Is Associated with an Increased Risk of Incident Atopic Dermatitis: A Multi-cohort Study with Metabolomic Insights
P6-E2 P—#2361	2026-10-19 15:42 · 7 min.	Xuan WANG Efficacy and Safety of Lebrikizumab Every 4 or 8 Weeks Maintenance Dosing Through Week 52 in Induction Responders with Moderate-to-Severe Atopic Dermatitis: Results from ADvance-ASIA Study
P6-E5 P—#2038	2026-10-19 16:03 · 7 min.	Elis Yuexian LEE Real-world experience of Baricitinib in Paediatric Atopic Dermatitis: A Retrospective Case series from a Singaporean Tertiary Paediatric Centre
Poster booth F
P6-F1 P—#2243	2026-10-19 15:35 · 7 min.	Qianyue XU The Diagnostic Transition from Eczema to Atopic Dermatitis in Real-World Practice: A 14-Year Study of Over One Million Patients
P6-F2 P—#2075	2026-10-19 15:42 · 7 min.	Man Fung TSOI Association between systemic immunomodulatory medications and achievement of super-response in patients with atopic eczema: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR)
P6-F4 P—#2351	2026-10-19 15:56 · 7 min.	Yuanyuan TIAN Effects of Early Application of an Oat-Containing Balm on Skin Barrier Development and Atopic Dermatitis-Related Responses in a Neonatal-Like 3D Skin Model
P6-F5 P—#2052	2026-10-19 16:03 · 7 min.	Eva KNÖPS The efficacy and safety of narrowband ultraviolet B in patients with atopic eczema: results of the UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema)
		Unassigned slot in Break Sessions
Poster booth ×

Slideshow on Displays

These presentations are only available on dedicated TV Booths during the whole meeting, and/or through the virtual portal.
No oral presentation is scheduled for this selection:

Note: Names and Titles will be displayed in full on October 16th, 2026.

Abstract	Author/Presenter
#2006	PP Epidemiology…
#2021	GD Characterization…
#2024	JY Real-world…
#2027	CAO Seasonal…
#2028	CAO Bridging…
#2033	XD A…
#2043	SL Delgocitinib…
#2044	VHP Interpreting…
#2046	NH Itch–Lesion…
#2047	XD Metabolic…
#2050	JZ Itch…
#2051	SR Dupilumab…
#2056	YY Postbiotics…
#2057	BL Effectiveness…
#2065	TH A…
#2067	XW Patients…
#2068	XW Patients…
#2070	YL Real-World…
#2077	YL Dermatologic…
#2081	ZG Nickel…
#2086	DA Sulphates…
#2088	YS Real-World…
#2091	NHR Therapeutic…
#2092	BD Adult…
#2100	TCX A…
#2105	XW Validation…
#2108	JZ Efficacy…
#2109	XW miRNA…
#2112	SL Construction…
#2113	SL Real-world…
#2114	SL Treatment…
#2122	JK Effectiveness…
#2124	BN When…
#2127	YZ Efficacy…
#2131	XN Safety,…
#2132	JZ Enhanced…
#2133	JZ Extended-Interval…
#2140	ABR Dupilumab…
#2142	PZ Exploring…
#2145	CJ International…
#2156	XM PVP/NaB-Loaded…
#2159	WZ A…
#2168	ZT Short…
#2169	ZT Performance…
#2171	YW Early…
#2172	CG Clinical…
#2186	JY Efficacy…
#2190	LM Real-World…
#2191	YL Inflammatory…
#2194	JY Dupilumab…
#2196	JS Real-World…
#2202	AM The…
#2207	CN Real-world…
#2208	YT Validation…
#2215	YX The…
#2219	YL The…
#2226	YR The…
#2236	WL Improvement…
#2238	JY Pediatric…
#2241	YG Benzalkonium…
#2245	VHP Real-world…
#2246	YZ A…
#2251	LD Gold…
#2253	FH Proteomic…
#2263	DW 4-Octyl…
#2265	JC Maternal…
#2269	HZ MrgprD…
#2273	HS An…
#2274	LM Opsin…
#2275	SD Atopic…
#2276	XT Epidermal…
#2279	FW Dose-Response…
#2283	JY A…
#2287	XW Tapinarof…
#2290	ZQ Sebum-induced…
#2301	QJ Malassezia…
#2309	ZW Clinical…
#2310	YD Environmental…
#2317	YR Effectiveness…
#2320	YR Relationship…
#2323	LM Molecular…
#2324	ZL Long-Term…
#2325	YZ Senescent…
#2328	BB Efficacy…
#2330	LM Smart…
#2331	YH Dupilumab…
#2333	YZ Mycosis…
#2341	TP Vigilance…
#2345	PS Dietary…
#2346	LM Pediatric…
#2355	LJS Prevalence…
#2376	AB Cleansing…
#2377	SF Comparison…

Submissions rejected or cancelled

Abstract	Author/Presenter
#2040	XD
#2054	JJ
#2079	TC
#2082	YZ
#2101	ANO
#2117	ADI
#2128	JZ
#2130	GCF
#2144	LJ
#2154	ONH
#2161	LM
#2166	GD
#2173	JP
#2184	LM
#2189	LW
#2195	LW
#2204	MZ
#2205	QZ
#2209	XW
#2211	YL
#2221	YR
#2225	KG
#2239	LZ
#2242	YL
#2255	XL
#2271	YL
#2272	PS
#2282	LM
#2284	YL
#2286	FW
#2293	YG
#2295	XL
#2296	YL
#2297	YR
#2300	YG
#2302	YL
#2305	YG
#2306	LM
#2307	JJ
#2308	WL
#2313	ZS
#2321	LM
#2334	AAA
#2335	YG
#2337	YZ
#2343	XX
#2354	LJS
#2362	LM